Fig. 2: ctDNA level changes during FOLFOX administration. | npj Precision Oncology

Fig. 2: ctDNA level changes during FOLFOX administration.

From: On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer

Fig. 2: ctDNA level changes during FOLFOX administration.The alternative text for this image may have been generated using AI.

In each panel, the tumor fraction as established by ichorCNA is displayed in red and the respective mutations in various colors. Before and after the FOLFOX cycle, the sum of longest diameters (SLD) for the target lesions is displayed. Fold changes in plasma ctDNA mAFs are each displayed in the right panel. a ctDNA levels of two patients (DR4 and DR7) with low ctDNA mAFs. b Three patients (DR3, DR8, DR9) with ctDNA mAFs that decrease below baseline values during the FOLFOX cycle. For reasons of clarity, the results of DR8 are shown in the bottom row. c Two patients (DR6, DR13) whose mAFs increased during the last 24 h of the treatment cycle to values higher than baseline levels. d ichorCNA, KRAS, and SLDs of patient DR12.

Back to article page